NasdaqGS - Nasdaq Real Time Price USD

Cullinan Therapeutics, Inc. (CGEM)

25.30

+6.05

(+31.43%)

At close: April 26 at 4:00 PM EDT

25.45

+0.15

(+0.59%)

After hours: April 26 at 7:50 PM EDT

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

A recent academic case study, published on April 22, examined using Amgen Inc’s (NASDAQ:AMGN) Blincyto, a bispecific CD3xCD19 T-cell engager, to treat a patient with severe systemic sclerosis. The findings have implications for Cullinan Therapeutics Inc’s (NASDAQ:CGEM) CLN-978, a similar CD19xCD3 bispecific T-cell engager. Most recently, Cullinan Therapeutics, formerly Cullinan Oncology, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in au

Benzinga 3 days ago

CGEM
+31.43%
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

CAMBRIDGE, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024. The data will include first results from the dose escalation cohort of CLN-619

GlobeNewswire 3 days ago

CGEM
+31.43%
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

Cullinan Therapeutics Inc (NASDAQ:CGEM), formerly Cullinan Oncology Inc, announced its plans to expand into autoimmune diseases and intends to pursue the development of CLN-978 in autoimmune diseases, with systemic lupus erythematosus (SLE) as a first indication. In SLE, the immune system of the body mistakenly attacks healthy tissue. The company believes that CLN-978 has the potential to be a first-in-class, off-the-shelf, disease-modifying treatment in autoimmune diseases with a differentiated

Benzinga 11 days ago

CGEM
+31.43%
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication Clinical observations from CLN-978 B-NHL study show rapid, deep, and sustained B cell depletion and clinical activity Corporate name change to Cullinan Therapeutics reflects strategic expansion into autoimmune diseases Cullinan Therapeutics to host a virtual investor event taking place on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) --

GlobeNewswire 12 days ago

CGEM
+31.43%
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Financing includes new and existing leading life sciences institutional investors Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028 Cullinan to host a virtual investor event on April 16 at 8:00 am ET CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (formerly Cullinan Oncology, Inc.) (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced

GlobeNewswire 12 days ago

CGEM
+31.43%
Cullinan changes name, pivots to autoimmune disease

The biotech says a dual-pronged antibody it’s developing could become an “off-the-shelf” alternative to cell therapies in development for lupus and other inflammatory conditions.

BioPharma Dive 12 days ago

CGEM
+31.43%
Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results

Strategic Developments and Financial Highlights Reflect Progress and Growth

GuruFocus.com last month

CGEM
+31.43%
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. last month

CGEM
+31.43%
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory multiple myeloma The company is exploring development of its CD19xCD3 T cell engager CLN-978 in autoimmune disorders Cash and investments of $468.3 million as of December 31, 2023 continues to provide runway into the second half of 2026 CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -

GlobeNewswire last month

CGEM
+31.43%
$Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma$
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of CLN-619 alone and in combination with pembrolizumab in solid tumors, with anticipated updated clinical data in Q2 2024 CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today annou

GlobeNewswire last month

CGEM
+31.43%
Cullinan Oncology to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced its participation in the following upcoming investor conferences: Jeffrey Jones, M.D., M.P.H., M.B.A., Chief Medical Officer, will participate in a Panel Discussion on Gynecologic Cancers at the TD Cowen 44th Annual Health Care Conference in Boston, MA on Tuesday, March 5, 2024, at 10

GlobeNewswire last month

CGEM
+31.43%
13 Best Booming Stocks to Buy Right Now

In this article, we will take a detailed look at the 13 Best Booming Stocks to Buy Right Now. For a quick overview of such stocks, read our article 5 Best Booming Stocks to Buy Right Now. Despite latest data showing elevated inflation and a decline in retail sales, some major investment firms are looking beyond the short-term market […]

Insider Monkey 2 months ago

OSCR

FATE

VKTX
Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

Corrine Savill, Chief Business Officer of Cullinan Oncology Inc (NASDAQ:CGEM), has sold 40,000 shares of the company on February 1, 2024, according to a recent SEC Filing.

GuruFocus.com 2 months ago

CGEM
+31.43%
Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares

Cullinan Oncology Inc (NASDAQ:CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology treatments, has reported an insider sell according to a recent SEC filing.

GuruFocus.com 3 months ago

CGEM
+31.43%
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed’s presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST). A live webcast of the presen

GlobeNewswire 4 months ago

CGEM
+31.43%
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic, targeted oncology therapies, today announced that the first patient has been dosed with CLN-617 in a Phase 1 clinical trial. This is a first-in-human, multi-center, open label study designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CLN-617 alone and in combination with pembrolizumab, a progra

GlobeNewswire 4 months ago

CGEM
+31.43%
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Cullinan to provide clinical data updates on three novel targeted oncology programs and complete enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study in 2024 Initial CLN-619 clinical biomarker data support mechanism of action and demonstrate monotherapy clinical activity in patients with tumors not typically responsive to checkpoint inhibitor therapy Cash and investment position of $482 million as of September 30, 2023 expected to provide runway into the second half of

GlobeNewswire 5 months ago

CGEM
+31.43%
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Five abstracts accepted for poster presentation at the Society for Immunotherapy of Cancer 2023 Annual Meeting Preliminary clinical biomarker data for anti-MICA/B antibody, CLN-619, supports proposed mechanism of action and demonstrates that the observed monotherapy clinical activity was seen in patients with tumors not typically responsive to checkpoint inhibitor therapy Data highlight progress of Cullinan’s diverse pipeline including CLN-619, an anti-MICA/B antibody; CLN-418, a B7H4X4-1BB-bisp

GlobeNewswire 5 months ago

CGEM
+31.43%
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) open to enrollment Initial monotherapy clinical data for CLN-619 presented at ASCO 2023 Annual Meeting; initiated monotherapy expansion cohorts in endometrial and cervical cancers First patient dosed in Phase 1 study of CLN-978 in relapsed/refractory (R/R) B Cell non-Hodgkin lymphoma (B-NHL) Cash and investment position of $512.1 million as of June 30, 2023 contin

GlobeNewswire 8 months ago

CGEM
+31.43%
$Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma$
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

CAMBRIDGE, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating CLN-978 for the treatment of relapsed/refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). The study is an open-label, dose-escalation, dose-expansion, and first-in-human study designed to evaluate the safety, tolerability, ph

GlobeNewswire 8 months ago

CGEM
+31.43%

Performance Overview

Return	CGEM	S&P 500
YTD	+148.28%	+6.92%
1-Year	+142.57%	+25.26%
3-Year	-19.66%	+22.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cullinan Therapeutics, Inc. (CGEM)

Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024

Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity

Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases

Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement

Cullinan changes name, pivots to autoimmune disease

Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma

Cullinan Oncology to Participate in Upcoming Investor Conferences

13 Best Booming Stocks to Buy Right Now

Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc

Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results

Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Performance Overview